Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
OKYO board/ team currently exploring the use of OKYO-101 analogs for other inflammatory diseases such as Uveitis and Allergic Conjunctivitis..... £multi-billion mkts/ on update expect major re-rate from currently over sold pos. again decent buying today
A dose ranging study in rabbits was performed to evaluate the effect of Chem-9 on corneal permeability and to assess the local irritation. Chem-9 was found to be effective in reducing corneal permeability and it shown no sign of local irritation. Potency of Chem-9 in reducing corneal permeability was comparable to cyclosporine (Restasis®; Allergan).
· Rabbit Ocular tolerance tests using Chem-9 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs of local irritation.
If results good fro here - its sure winner ealry days - but next update and ist nulti-bagger from here.
excellent entry at 12p. well don if you buyig and holding.
of the their eye drug very soon - that could be next news pending - which will be send the s soaring over 30p - as this market is multi-billion dollar and OKYO is right at the center.
we will have great week here. imho.
Dr. Napoleone Ferrara stated: “I am delighted to join OKYO Pharma as a member of the SAB. OKYO’s focus on the development of long-acting GPCR agonists to treat dry eye and ocular pain is scientifically sound and promising. GPCRs are key targets for pharmacological intervention in a variety of diseases. My expertise in ocular angiogenesis should complement these efforts and I look forward to an exciting collaboration”.
Willy Simon, Chairman of OKYO said: “We are very excited about Dr. Napoleone Ferrara’s addition to the OKYO team. Very few scientists have invented two different blockbuster drugs such as Avastin® and Lucentis®. Lucentis® has become one of the major blockbuster drugs to treat eye disease and Napoleone’s experience will be a huge value added to Okyo’s drug development effort.”
Dr. Napoleone Ferrara’s has also commercilaised simliar drugs - in this multi-billion dollar market.
So what is next.....
Dr. James Khodabakhsh specializes in complex surgeries of the eye and is one of the most sought after surgeons in Los Angeles and is the Medical Director at the Beverly Hills Institute of Ophthalmology.
Dr. Khodabakhsh has performed over 40,000 eye surgical procedures including LASIK, Glaucoma and cataract surgeries. Dr. Khodabakhsh is also presently the Chief and Chairman of the Department of Ophthalmology at the Cedars Sinai Medical Centre where he is involved in multiple Clinical trials.
“I’m honored to lead the SAB board of Okyo pharmaceuticals. I’m looking forward to building a first class team and accelerate the clinical development of our compounds for the treatment of dry eyes and inflammation. This space has tremendous potential for growth and I truly feel we can add to it with our molecules,” said Dr. Khodabakhsh.
Willy Simon, Chairman of OKYO said: "It gives me great pleasure to have Dr. Khodabakhsh leading and chairing the new Scientific Advisory Board and I am honoured that he considers the Company's clinical pipeline to be of clinical interest in the context of his treating patients in the field. We look forward to fully utilising his deep experience and clinical knowledge to assist in driving the development of Chemerin to its nest stages of development."
on a friday....! looks liek will rocket on Monday and next week.
Yep, missed a trick yesterday, being marked back up by MMs big time! Went into ODX instead, cruel game this lol
Blast, I was tempted to buy yesterday after the drop - as TILS moving up well although no real correlation.
And up she goes today, nother opportunity lost as not going in now...I like a head start on the price
This information is on the company website under the News section. It merely lists the resolution (numbers only), and the results of the proxy vote for each one. All were virtually accepted unanimously - mostly 100% in favour of each resolution. In other words the company is just fulfilling certain statutory obligations - there is no news as such.
he share price has declined again - to 10.25p with very little volume. This is not significant, and IMO is not as a consequence of the AGM. There have been strategic manoeuvres within the company recently, and as an investor, I will need to continue to trust the judgement of the experienced board of directors, and await a further news update.
Spinaker, this bb is like a desert, devoid of any life or activity. Was invested in here at 10p but have gradually withdrawn funds and put into the likes of Syme, Skin and some others. Might get back into this one when there is a bit more life from the BOD. I like the fundamentals of this company and have some good things in the pipeline.
now on trading 212 could be a possible reason for the sudden increase
Just checked this board to see if anyone has posted. Since I bought in at 16.5p this SP has dropped like Tiziana every day. Just now a sudden 7% increase. No idea why!
And now 12p......very similar action to TILS.
Hi everyone,
Is there a Calendar of all expected releases of trials for the UK, like that of the FDA? Date form the MHRA?
cheers
Gromshy
"Okyo is being set up like Tiziana"
What to fall like catching a knife?
More ducks lined up ,
It's coming get in early
The ducks are lining up.
Yesterday I said this is going to be big ,wrong ,
It's going to be huge .
Okyo is being set up like Tiziana,
You are going to see great things
These guys know what makes a company
I can see this really growing
Thanks Hullaballoola.
Good
Hi All,
Newbie here.
Is the news of plans to dual list good or bad?
thanks
Nasdaq here we come baby
OKYO Pharma shares took a battering last week but investors might soon be on the receiving end of some welcome news.
Earlier this month, American eye surgeon Dr James Khodabakhsh joined the firm’s scientific advisory board as chairman. He is head of the Cedars-Sinai clinic in Beverly Hills, Los Angeles, which treats Hollywood stars and directors as well as popular singers.
Now City sources say the company - which is developing a treatment for dry eye - might see another high-profile healthcare scientist join in the next few weeks.
The new recruit is said to be the award-winning inventor of two drugs that generated sales of more than $11 billion.